|
| Status |
Public on Jun 28, 2024 |
| Title |
CRISPR-Cas screen in ILC2 identifies Mef2d as a regulator of GATA3 and type-2 immunity |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
Genome binding/occupancy profiling by high throughput sequencing
Other
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation(s) |
38935708 |
| |
| Submission date |
Sep 01, 2023 |
| Last update date |
Aug 09, 2024 |
| Contact name |
Ana Ferreira |
| Organization name |
MRC - Laboratory of Molecular Biology
|
| Street address |
Francis Crick Avenue, Cambridge Biomedical Campus
|
| City |
Cambridge |
| ZIP/Postal code |
CB2 0QH |
| Country |
United Kingdom |
| |
|
| Platforms (2) |
| GPL21103 |
Illumina HiSeq 4000 (Mus musculus) |
| GPL30172 |
NextSeq 2000 (Mus musculus) |
|
| Samples (36)
|
|
| This SuperSeries is composed of the following SubSeries:
|
| GSE242029 |
CRISPR screens and ILC2-targeted Boolean circuitry reveal Mef2d-potentiation of type-2 immunity [RNA-Seq] |
| GSE242030 |
CRISPR-Cas screen in ILC2 identifies Mef2d as a regulator of GATA3 and type-2 immunity [ChIP-Seq] |
| GSE242146 |
CRISPR-Cas screen in ILC2 identifies Mef2d as a regulator of GATA3 and type-2 immunity [ATAC-Seq] |
| GSE262028 |
CRISPR-Cas screen in ILC2 identifies Mef2d as a regulator of GATA3 and type-2 immunity [CRISPR screen] |
|
| Relations |
| BioProject |
PRJNA1011854 |
Less...
More...